Table 2. Characteristics of HDACi-resistant or -sensitive HMCLs.
| HMCL name | IL-6 dependencea | Originb | Diseasec | Patient sampled | Gender | Isotype | t(14q32 or 22q11) | Target genes | Ras | TP53 | CD45 | HMCL classification |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
TSA-resistant HMCLs | ||||||||||||
| XG7 | + | MN | MM | PB | F | Ak | t(4;14) | MMSET | mut | wt | +/− | MS |
| XG20 | ++ | MN | PCL | PB | M | l | t(4;14) | MMSET | wt | abn | − | MS |
| AMO1 | − | CO | PCT | AF | F | Ak | t(12;14) | Unknown | wt | wt | + | CD-2L |
| JJN3 | − | CO | MM | PE | F | Ak | t(14;16) | c-Maf | mut | abn | +/− | MF |
| LP1 |
− |
CO |
MM |
PB |
F |
Gl |
t(4;14) |
MMSET/FGFR3 |
wt |
abn |
− |
MS |
|
TSA-sensitive HMCLs | ||||||||||||
| XG5 | ++ | MN | MM | PB | F | l | t(11;14) | CCND1 | wt | abn | − | CD-1 |
| XG6 | ++ | MN | MM | PB | F | Gl | t(16;22) | c-Maf | wt | wt | + | CTA/MF |
| XG13 | ++ | MN | PCL | PB | M | Gl | t(14;16) | c-Maf | wt | abn | + | MF |
| XG16 | ++ | MN | PCL | PB | M | k | None | None | mut | abn | + | CTA/FRZB |
| XG21 | ++ | MN | MM | PE | M | l | t(11;14) | CCND1 | wt | wt | + | CD-1 |
Abbreviations: AF=ascitic fluid; BM=bone marrow; CO=collected; F=female; HDACi=histone deacetylase inhibitor; HMCL=human myeloma cell line; IL=interleukin; M=male; MM=multiple myeloma; MN=Montpellier or Nantes; PB=peripheral blood; PCL=plasma cell leukemia; PCT=plasmacytoma; PE=pleural effusion; TSA=trichostatin A.
a
++, if growth is strictly dependent on adding exogenous IL-6; +, if dependent on adding exogenous IL-6; −, if not.
b
Origin of the HMCL: MN, CO.
c
Disease at diagnosis: MM, PCL, PCT.
d
Origin of the sample: AF, BM, PE, PB.